On May 31, 2019 BerGenBio ASA (OSE:BGBIO), reported that it will share its latest updates and data on an investor call on 4 June 2019, during the annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting (Press release, BerGenBio, MAY 31, 2019, View Source [SID1234536747]). BerGenBio’s senior management team will be hosting the call at 15:30 CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dial-in details are:

Standard International Dial-In: +44 (0) 2071 928000
United States Dial-In: 16315107495
Participant Code: 4352428
The call will focus on two peer reviewed abstracts on Phase II clinical data with bemcentinib in the treatment of Non-Small Cell Lung Cancer and Acute Myeloid Leukemia.